Lv31
300 积分 2025-03-10 加入
IBD Matchmaking: Rational Combination Therapy
1小时前
待确认
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已完结
Laboratory Markers of Platelet Production and Turnover
1个月前
已完结
Diet outperforms microbial transplant to drive microbiome recovery in mice
1个月前
已完结
APOB-48 shows potential as a biomarker to evaluate treatment response with apraglutide in short bowel syndrome, intestinal failure and colon-in-continuity
2个月前
已关闭
Can amylin-based drugs upstage GLP-1 agonists?
2个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2个月前
已完结
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials
2个月前
已完结
Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn's disease or ulcerative colitis in adults: a meta-analysis
2个月前
已完结
Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease
2个月前
已完结
皖公网安备34019202002308
